Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
The upcoming Non-Significant Risk (NSR) study will enroll 50 expectant mothers in the U.S. to evaluate the safety and effectiveness of PregnaOne during home use. The study is designed to generate foundational evidence to support future regulatory approval in the U.S. Curavit will manage all aspects of the trial, including IRB submissions, site selection, contract and monitoring, data management, clinical data capture software selection, data analytics, and preparation of the Clinical Study Report (CSR).
'We are honored to support Nestmedic in bringing PregnaOne to market,' said Joel Morse, CEO and Co-founder of Curavit Clinical Research. 'Their mission to improve prenatal care through remote monitoring perfectly aligns with Curavit's vision to partner with innovative medical device companies that are working to expand access to healthcare.'
Trial Highlights:
'We are building technology with empathy at its core,' said Jacek Gnich, CEO of Nestmedic. 'Curavit's innovation forward approach, medical device expertise, and deep clinical trial experience make them the ideal partner to run this pivotal study in the U.S.'
About Curavit Clinical Research
Curavit Clinical Research, The Innovation-CRO, designs and executes modern clinical trials for medical devices, digital therapeutics, and novel pharmaceuticals. Headquartered in Boston, Curavit operates nationwide with additional offices in New York, Salt Lake City, and San Diego. Learn more at www.curavit.io.
About Nestmedic S.A.
Nestmedic is a Polish medtech company redefining prenatal care with PregnaOne, an AI-enabled remote monitoring solution that empowers patients and providers with real-time, continuous insight into fetal and maternal well-being.
View original content to download multimedia: https://www.prnewswire.com/news-releases/nestmedic-selects-curavit-clinical-research-as-us-cro-partner-for-pioneering-prenatal-monitoring-trial-302509048.html
SOURCE Curavit Clinical Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Abacus Global Management Announces Successful Completion of Exchange Offer and Consent Solicitation
ORLANDO, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ('Abacus' or the 'Company') (NASDAQ: ABL), a leader in the alternative asset management space, today announced the completion of its previously announced exchange offer (the 'Offer') and consent solicitation (the 'Consent Solicitation') relating to its (i) outstanding public warrants (the 'public warrants') and (ii) outstanding private placement warrants (the 'private placement warrants' and, together with the public warrants, the 'warrants') to purchase shares of common stock, par value $0.0001 per share, of the Company ('common stock'). The Company's common stock and public warrants are listed on the Nasdaq Capital Market (the 'Nasdaq') under the symbols 'ABL' and 'ABLLW,' respectively. The Company issued 4,183,160 shares of common stock in exchange for the warrants tendered in the Offer. On July 30, 2025, the Company and Continental Stock Transfer & Trust Company entered into the related amendment to the warrant agreement governing the warrants (the 'Warrant Amendment'). Pursuant to the Warrant Amendment, the Company has exercised its right to exchange each warrant that is outstanding upon the closing of the Offer for 0.207 shares of common stock per warrant, which is a ratio 10% less than the exchange ratio applicable to the Offer (the 'Post-Offer Exchange'). The Company has fixed the date for the Post-Offer Exchange as August 14, 2025. As a result of the completion of the Offer and the Post-Offer Exchange, no warrants will remain outstanding. Accordingly, the public warrants are expected to be suspended from trading on the Nasdaq as of the close of business on August 14, 2025, and will be delisted. The shares of common stock will continue to be listed and trade on the Nasdaq under the symbol 'ABL.' Following completion of the Offer, there are approximately 102,050,981 shares of common stock outstanding (an increase of approximately 4% from prior to the closing of the Offer), and following completion of the Post-Offer Exchange there will be approximately 102,555,154 shares of common stock outstanding (an increase of approximately 5% from prior to the closing of the Offer and the Post-Offer Exchange). The Company engaged SG Americas Securities, LLC as the dealer manager for the Offer and Consent Solicitation, D.F. King & Co., Inc. as the information agent for the Offer and Consent Solicitation, and Continental Stock Transfer & Trust Company served as the exchange agent for the Offer and Consent Solicitation. About Abacus Abacus Global Management (NASDAQ: ABL) is a leading financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. With a focus on longevity-based assets and personalized financial planning, Abacus leverages proprietary data analytics and decades of industry expertise to deliver innovative solutions that optimize financial outcomes for individuals and institutions worldwide. Contacts: Investor RelationsRobert F. Phillips – SVP Investor Relations and Corporate Affairs rob@ 290-1198 David Jackson – Managing Director of Investor Relations david@ 299-0716 Abacus Global Management Public Relationspress@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Meta Platforms Jumps on Strong Q2 Earnings and Upbeat Guidance
Meta Platforms (META, Financials) jumped in after-hours trading Wednesday after blowing past Wall Street's Q2 estimates and projecting stronger-than-expected Q3 sales. Warning! GuruFocus has detected 5 Warning Sign with META. For the June quarter, profit came in at $7.14 per share on revenue of $47.52 billion, handily beating analyst targets. Family daily active people rose 6% from last year to 3.48 billion. The company guided for Q3 revenue near $49 billion, signaling confidence in its AI-driven growth. Capex is now expected at $66 billion$72 billion for 2025, slightly narrower than before. Meta also flagged a likely slowdown in Q4 growth as it laps last year's strong gains. Investors will be watching whether AI continues to fuel revenue and ad demand into year-end. This article first appeared on GuruFocus.
Yahoo
20 minutes ago
- Yahoo
SpaceX faces two new lawsuits alleging safety‐related retaliation
When longtime supervisor Robert Markert warned SpaceX leaders that one part of the rocket fairing recovery process could 'easily cause serious injury or death,' he alleges he was ignored because 'it was the more economical solution,' according to a recently filed lawsuit. A few months later, he was out of the job. Markert is one of two former SpaceX employees who have filed separate wrongful-termination lawsuits, both of which were removed to federal court earlier this month. The two complaints make similar allegations about how speed and cost-saving triumphed over other considerations – including safety. The lawsuits arrive as SpaceX races to get its Starship ultra-heavy rocket ready to complete missions for NASA, commercial customers, and to launch the company's Starlink satellite internet service. Beyond the Starship program, SpaceX also operates the most frequently launched rocket in history, the Falcon 9, which has flown 87 times so far this year. Markert spent 13 years at the company before being terminated in April. He alleges that during his tenure technicians were sometimes required to work 15 to 20 days in a row, but when he brought this up to supervisors, he was told 'the schedule comes first.' That punishing schedule, performed in a high-stress environment, resulted in injuries Markert alleges the ship technicians were too afraid to report. When Markert suggested the company prioritize trainings and certifications, he was told 'there is no time for that and the company would not spend money on it,' according to the complaint. The second lawsuit, filed by SpaceX plumber David Lavalle, alleges he was fired after the company failed to accommodate multiple work-related injuries, including a fractured foot, severe neck pain, injuries to his back and shoulders, and wrist pain. While Lavalle filed for worker's compensation for some of these injuries, he did not do so for all for fear of retaliation, the complaint says. Nine days after requesting medical leave for gout-induced knee pain, Lavalle was terminated. Lavalle, who is 60 years old, joined the company in 2014. He alleges in the complaint he was part of a wave of firings of older staff members, led in part by 28-year-old Scott Hiler, who SpaceX hired as a new senior manager late last year. A lawyer representing Markert declined comment, while Lavalle's attorney did not immediately respond to TechCrunch's request. SpaceX did not respond to TechCrunch's request for comment. Recent reporting from TechCrunch showed that SpaceX outpaced its peers in worker injury rates for 2024. Data from the Occupational Safety and Health Administration showed that the Starbase complex in Texas recorded an injury rate of 4.27 per 100 workers last year, nearly triple the aerospace manufacturing average of 1.6. Markert, a resident of Los Angeles County, doesn't expressly state where he worked at SpaceX. The lawsuit does note he worked with ship technicians. SpaceX's west coast rocket fairing recovery operations count the highest injury rates of all SpaceX sites, the OSHA logs show, with an injury rate of 7.6 per 100 workers for the west coast operations. Both complaints were filed in Los Angeles County Superior Court and were then removed by SpaceX to the U.S. District Court for the Central District of California. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
